216 related articles for article (PubMed ID: 21348384)
1. Prospective multicenter observational study of encapsulating peritoneal sclerosis with neutral dialysis solution--the NEXT-PD study.
Kawanishi H; Nakayama M; Miyazaki M; Honda K; Tomo T; Kasai K; Nakamoto H;
Adv Perit Dial; 2010; 26():71-4. PubMed ID: 21348384
[TBL] [Abstract][Full Text] [Related]
2. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study.
Nakayama M; Miyazaki M; Honda K; Kasai K; Tomo T; Nakamoto H; Kawanishi H
Perit Dial Int; 2014; 34(7):766-74. PubMed ID: 24497585
[TBL] [Abstract][Full Text] [Related]
3. Encapsulating Peritoneal Sclerosis.
Alston H; Fan S; Nakayama M
Semin Nephrol; 2017 Jan; 37(1):93-102. PubMed ID: 28153198
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription.
Habib AM; Preston E; Davenport A
Nephrol Dial Transplant; 2010 May; 25(5):1633-8. PubMed ID: 20037174
[TBL] [Abstract][Full Text] [Related]
5. [Peritoneal dialysis: a time-limited therapy because of encapsulating peritoneal sclerosis?].
Bertoli SV; Musetti C
G Ital Nefrol; 2010; 27(5):464-8. PubMed ID: 20922677
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for encapsulating peritoneal sclerosis in long-term peritoneal dialysis: a retrospective observational study.
Nakao M; Yokoyama K; Yamamoto I; Matsuo N; Tanno Y; Ohkido I; Hayakawa H; Ikeda M; Yamamoto H; Hosoya T
Ther Apher Dial; 2014 Feb; 18(1):68-73. PubMed ID: 24499086
[TBL] [Abstract][Full Text] [Related]
7. [Peritoneal dialysis: a time-limited therapy because of encapsulating peritoneal sclerosis? No, but better approaches are available].
Garosi G
G Ital Nefrol; 2010; 27(5):456-63. PubMed ID: 20922676
[TBL] [Abstract][Full Text] [Related]
8. Long-term peritoneal dialysis and encapsulating peritoneal sclerosis in children.
Honda M; Warady BA
Pediatr Nephrol; 2010 Jan; 25(1):75-81. PubMed ID: 21476232
[TBL] [Abstract][Full Text] [Related]
9. Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients: the experience of the Italian Registry of Pediatric Chronic Dialysis.
Vidal E; Edefonti A; Puteo F; Chimenz R; Gianoglio B; Lavoratti G; Leozappa G; Maringhini S; Mencarelli F; Pecoraro C; Ratsch IM; Cannavò R; De Palo T; Testa S; Murer L; Verrina E;
Nephrol Dial Transplant; 2013 Jun; 28(6):1603-9. PubMed ID: 23585587
[TBL] [Abstract][Full Text] [Related]
10. The use of biocompatible solutions does not prevent development of encapsulating peritoneal sclerosis.
Tejde M; Linder M; Karsberg M; Ekspong A
Perit Dial Int; 2010; 30(1):113-4. PubMed ID: 20056992
[No Abstract] [Full Text] [Related]
11. Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients After Kidney Transplantation.
Ayar Y; Ersoy A; Ocakoglu G; Gullulu E; Kagızmanlı H; Yıldız A; Oruc A; Yavuz M; Gullulu M; Dilek K
Transplant Proc; 2018; 50(1):160-164. PubMed ID: 29407302
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of encapsulating peritoneal sclerosis: lessons from findings of the past three decades in Japan.
Nakayama M; Miyazaki M; Hamada C; Ito Y; Honda K;
Clin Exp Nephrol; 2023 Sep; 27(9):717-727. PubMed ID: 37278945
[TBL] [Abstract][Full Text] [Related]
13. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
14. Past and present perspectives on encapsulating peritoneal sclerosis.
Kawanishi H; Shintaku S; Banshodani M; Hashimoto S
Contrib Nephrol; 2015; 185():87-97. PubMed ID: 26023018
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary clinical strategies for encapsulating peritoneal sclerosis in peritoneal dialysis: update from Japan.
Nakayama M; Terawaki H
Int J Urol; 2014 Aug; 21(8):755-61. PubMed ID: 24673567
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Peritoneal Dialysis in Japan.
Ito Y; Tawada M; Tine S; Mizuno M; Suzuki Y; Katsuno T
Contrib Nephrol; 2018; 196():123-128. PubMed ID: 30041216
[TBL] [Abstract][Full Text] [Related]
17. Absence of Post-Transplantation Encapsulating Peritoneal Sclerosis after Relatively Short Exposure to Peritoneal Dialysis: Prospective Analysis Using Repeated Abdominal CT Scanning.
Abrahams AC; van Gelder MK; van der Veer JW; de Jong PA; van Leeuwen MS; Boer WH
Perit Dial Int; 2017; 37(4):443-450. PubMed ID: 28676511
[TBL] [Abstract][Full Text] [Related]
18. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
19. "Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?
Misra PS; Nessim SJ; Perl J
Semin Dial; 2017 Mar; 30(2):164-173. PubMed ID: 28251697
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal dialysis solutions low in glucose degradation products: clinical experience and outcomes.
Diaz-Buxo JA
Adv Perit Dial; 2007; 23():132-4. PubMed ID: 17886619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
